Related Experiment Video
Updated: Jan 24, 2026

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024
Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy
Dong Gun Kim1, Kyu-Seok Hwang2, Se Hwan Ahn1
1Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
Insights
A novel compound, 20e, effectively reduced seizures in zebrafish and mouse models of Severe Myoclonic Epilepsy of Infancy (SMEI). This promising drug candidate also normalized neuronal activity and demonstrated a favorable safety profile.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Severe Myoclonic Epilepsy of Infancy (SMEI), or Dravet syndrome, is a severe epileptic encephalopathy often caused by SCN1A mutations.
- It leads to intractable seizures and significant developmental impairment, necessitating new therapeutic strategies.
Purpose of the Study:
- To identify novel chemotypes for SMEI treatment.
- To evaluate the efficacy and safety of a novel compound, 20e, in preclinical models of SMEI.
Main Methods:
- Established a Nav1.1 (scn1lab) knockout zebrafish model for high-throughput chemical screening.
- Tested compound 20e in zebrafish and SCN1A+/- mouse models, and in SMEI patient-derived iPSC neurons.
- Investigated the mechanism of action, including effects on 5-HT levels and TPH2, and assessed pharmacokinetic and safety profiles.
Main Results:
- Compound 20e demonstrated potent antiseizure efficacy in zebrafish, outperforming repositioned drugs.
- In SCN1A+/- mice, 20e reduced seizure severity, delayed onset, and suppressed hyperactivity.
- 20e normalized pathological neuronal activity in iPSC-derived neurons and showed favorable BBB penetration, oral pharmacokinetics, and safety.
Conclusions:
- Compound 20e exhibits significant therapeutic potential for SMEI.
- The compound's mechanism involves elevating 5-HT levels via TPH2 upregulation.
- 20e represents a promising candidate for further development as an SMEI therapeutic agent.
Abstract:
Severe myoclonic epilepsy of infancy (SMEI, Dravet syndrome), which is mainly caused by the SCN1A mutation, is a severe epileptic encephalopathy that manifests in infancy and leads to intractable seizures and developmental impairment. To discover new therapeutic chemotypes, we established a Nav1.1 (scn1lab) KO zebrafish model for chemical screening and identified novel 1,3,4-oxadiazol-2(3H)-one derivatives. Among them, compound 20e showed the most potent antiseizure efficacy in zebrafish behavioral assays and significantly reduced locomotion-related seizure parameters compared with repositioned drugs. In SCN1A+/- mice, 20e reduced seizure severity, delayed onset, and suppressed hyperactivity. Notably, 20e normalized pathological spike and burst activity in SMEI patient-derived iPSC neurons. Mechanistically, 20e appears to elevate 5-HT levels via TPH2 upregulation. It demonstrated reasonable BBB penetration, favorable oral PK, and good safety without notable hERG inhibition, cytotoxicity, mutagenicity, or acute toxicity. Taken together, compound 20e shows promise as a therapeutic agent for SMEI.
Related Concept Videos
Socioemotional Development during Infancy
Primary Temperament Types
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Molecules and Compounds
Positive Regulator Molecules
Types of Signaling Molecules
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion

